Key result
Baseline HbA1c ≥ 7.2% was associated with a significantly increased risk of 1-year all-cause mortality compared to HbA1c <5.5% after acute ischemic stroke (OR 2.45; P for trend=0.009).
Why the study?
Does elevated baseline HbA1c increase the risk of 1-year all-cause mortality and poor functional outcome in patients with acute ischemic stroke?
Cohort (n=2,186)
Yes
Does elevated baseline HbA1c increase the risk of 1-year all-cause mortality and poor functional outcome in patients with acute ischemic stroke?
Odds Ratio: 2.45
p-value: p=0.009
Elevated baseline HbA1c ≥ 7.2% is an independent predictor of 1-year all-cause mortality after acute ischemic stroke, particularly in patients without a history of diabetes or post-stroke insulin use.
No takes yet. Share an insight, caveat, or question.
HbA1c ≥7.2% flags higher post-stroke mortality risk; leaves open whether glycemic control modifies 1-year outcomes.
Wu et al. (2014) conducted a cohort in acute ischemic stroke (n=2,186). Elevated HbA1c (≥ 7.2%) vs. HbA1c <5.5% was evaluated on 1-year all-cause mortality (OR 2.45, p=0.009). Baseline HbA1c ≥ 7.2% was associated with a significantly increased risk of 1-year all-cause mortality compared to HbA1c <5.5% after acute ischemic stroke (OR 2.45; P for trend=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: